CG Oncology, Inc. (CGON)

CG Oncology Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-88.04	-48.61	-35.44	-12.84
Depreciation & Amortization	0.03	0.02	0.02	0.01
Other Amortization	-	0	0.01	0.01
Loss (Gain) From Sale of Investments	-4.99	-2.88	-	-
Stock-Based Compensation	11.4	1.53	0.68	1.11
Other Operating Activities	-0.02	0.82	0.5	0.02
Change in Accounts Receivable	-0.69	-	-	-
Change in Accounts Payable	3.28	2.01	-0.02	0.58
Change in Other Net Operating Assets	0.32	1.43	4.46	-2.55
Operating Cash Flow	-78.71	-45.68	-29.8	-13.65
Capital Expenditures	-0.23	-	-0.01	-0.1
Investment in Securities	-300.53	-121.2	-55.34	-
Investing Cash Flow	-300.76	-121.2	-55.35	-0.1
Long-Term Debt Issued	-	-	-	15.2
Long-Term Debt Repaid	-0.37	-16.29	-	-
Net Debt Issued (Repaid)	-0.37	-16.29	-	15.2
Issuance of Common Stock	632.07	2.08	0.17	0.25
Other Financing Activities	-3.42	-3.83	-0.47	-
Financing Cash Flow	628.28	87	119.69	15.45
Net Cash Flow	248.8	-79.88	34.54	1.7
Free Cash Flow	-78.95	-45.68	-29.82	-13.75
Free Cash Flow Margin	-6931.26%	-22391.67%	-15611.52%	-132.76%
Free Cash Flow Per Share	-1.26	-10.55	-7.97	-3.77
Cash Interest Paid	-	0.38	1.09	0.31
Levered Free Cash Flow	-59.08	-28.07	-16.95	-
Unlevered Free Cash Flow	-59.08	-28.07	-16.96	-
Change in Net Working Capital	-1.38	-5.04	-4.39	-

Updated Mar 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q